Clinical phagic therapy: New challenges (Q3137650): Difference between revisions
Jump to navigation
Jump to search
(Created claim: summary (P836): Hospital-acquired infections are a major problem in the industrialised world, with incidence rates of 5 % and 7.1 % in the United States (USA) and the European Union (EU), respectively. On the other hand, multi-drug-resistant bacteria, MDR (Superbacteria) are considered a major health safety challenge in the 21st century (Joint Statement by the Ministers of Science of the G8 countries, meeting in London prior to the G8 summit in Northern Ireland...) |
(Changed label, description and/or aliases in en: translated_label) |
||
| label / en | label / en | ||
Clinical phagic therapy: New challenges | |||
Revision as of 12:35, 12 October 2021
Project Q3137650 in Spain
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Clinical phagic therapy: New challenges |
Project Q3137650 in Spain |
Statements
73,200.0 Euro
0 references
91,500.0 Euro
0 references
80.0 percent
0 references
1 January 2017
0 references
31 March 2020
0 references
FUNDACION PROFESOR NOVOA SANTOS
0 references
43°29'36.67"N, 8°12'51.26"W
0 references
15030
0 references
Las infecciones adquiridas en el hospital son un importante problema en el mundo industrializado, con tasas de incidencia del 5% y 7,1% en los Estados Unidos (EEUU) y la Unión Europea (UE), respectivamente. Por otra parte, las bacterias resistentes a múltiples fármacos, MDR ( Superbacterias ) se consideran Un importante desafío a la seguridad de la salud del siglo XXI (Declaración conjunta de los ministros de ciencia de los países del G8, reunidos en Londres antes de la cumbre del G8 en Irlanda del Norte, 2013). La tasa de descubrimiento de compuestos para TERAPIA ANTIMICROBIANAS ha disminuido en las últimas décadas. Nuevas líneas de tratamiento anti-infeccioso han comenzado a ser estudiadas, incluyendo la TERAPIA FÁGICA. Sin embargo, esta terapia es muy específica y presenta algunos problemas en relación con las Superbacterias (Patógenos del grupo ESKAPE: Enterococcus faecium, Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa y Enterobacter spp). El principal objetivo de este ambicioso proyecto es innovar en la TERAPIA FÁGICA (Terapia Convencional Fágica, Terapia de Fagos Modificados, Terapia a partir de proteínas que portan los Fagos y Terapia Combinada) partiendo de los FAGOS CLÍNICOS aislados en patógenos del grupo ESKAPE. Para ello estudios genómicos/funcionales in vitro e in vivo, desarrollo de cócteles de fagos líticos así como estudios estructurales de proteínas (dianas para el desarrollo de nuevos tratamientos) serán llevados a cabo. (Spanish)
0 references
Hospital-acquired infections are a major problem in the industrialised world, with incidence rates of 5 % and 7.1 % in the United States (USA) and the European Union (EU), respectively. On the other hand, multi-drug-resistant bacteria, MDR (Superbacteria) are considered a major health safety challenge in the 21st century (Joint Statement by the Ministers of Science of the G8 countries, meeting in London prior to the G8 summit in Northern Ireland, 2013). The rate of discovery of compounds for ANTIMICROBIAN TERAPY has decreased in recent decades. New lines of anti-infectious treatment have begun to be studied, including phagic THEREAPY. However, this therapy is very specific and presents some problems in relation to Superbacteria (Patogens of the Eskape group: Enterococcus faecium, Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa and Enterobacter spp). The main objective of this ambitious project is to innovate in the phagic Therapy (conventional phagic therapy, Modified Fages Therapy, Therapy from proteins that carry phages and Combined Therapy) starting from the CLINICAL FAGS isolated in pathogens of the Eskape group. For this purpose genomic/functional studies in vitro and in vivo, development of lithic phage cocktails as well as structural studies of proteins (dians for the development of new treatments) will be carried out. (English)
12 October 2021
0 references
Coruña, A
0 references
Identifiers
PI16_01163
0 references